MYO9A

Across TCGA pan-cancer cohorts, MYO9A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYO9A data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYO9A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO9A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where MYO9A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	0.274	1.000	.002	50	view →
CCRCC	DFS	Tertile	All	0.906	0.443	.012	21	view →
PDAC	OS	Quartile	II,III,IV	0.906	1.000	.006	10	view →
LUAD	DFS	Quartile	II,III,IV	0.178	0.694	.033	5	view →
LSCC	OS	Quartile	III,IV	0.309	0.972	.004	5	view →
HNSC	DFS	Median	III,IV	0.697	0.526	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYO9A–UCEC (DFS)

Open the UCEC breakdown →